SOPHiA GENETICS and Jessa Ziekenhuis Announce Precision Oncology Partnership from the European Congress of Pathology

Core Insights - SOPHiA GENETICS has announced a collaboration with Jessa Ziekenhuis to enhance genomic testing and oncology research for cancer patients in Belgium [1][8] - The partnership aims to unify next-generation sequencing (NGS) workflows under a single platform, improving efficiency and compliance with national guidelines [2][5] Group 1: Collaboration Details - Jessa Ziekenhuis processes over 3,000 oncology DNA and RNA samples annually and will implement SOPHiA DDM™ across its pathology operations [2] - The collaboration will involve six SOPHiA GENETICS applications tailored for solid tumors, hematologic malignancies, and liquid biopsy analysis [3] - The integration of SOPHiA GENETICS' cloud-based platform with Jessa Ziekenhuis's Laboratory Information Management System (LIMS) will streamline operations [4] Group 2: Expected Benefits - Jessa Ziekenhuis anticipates a reduction in hands-on time by 30-50% and overall costs by up to 25% through the unified NGS operation [5] - The collaboration will enhance testing turnaround times and improve the scalability of sequencing services [5][6] - The SOPHiA DDM™ Dispatch feature will allow Jessa Ziekenhuis to share a NovaSeq sequencer with AZ Delta, optimizing sequencing capacity and knowledge sharing [6] Group 3: Strategic Importance - The partnership exemplifies SOPHiA GENETICS' commitment to supporting healthcare institutions in scaling genomics capabilities while ensuring quality and efficiency [8] - This collaboration strengthens SOPHiA GENETICS' presence in European hospital networks, promoting data-driven precision medicine [8][9]